日本語English简体中文 繁體中文

4594 BrightPath Biotherapeutics Co.,Ltd.ブライトパス・バイオTSE Growth / Pharmaceuticals

0 posts

BrightPath Biotherapeutics Co.,Ltd. (4594) at a glance

Code
4594
Company
BrightPath Biotherapeutics Co.,Ltd.
Local name
ブライトパス・バイオ
Market
TSE Growth
Sector
Pharmaceuticals
Share price
¥36.0 -2.00 (-5.26%) Nov 20 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

BrightPath Biotherapeutics Co.,Ltd. (4594) Stock Price HistoryNear an all-time low

BrightPath Biotherapeutics Co.,Ltd. closed at ¥36.0 on Nov 20, 2026, −12.2% over 1 month, −39.0% over 1 year.

2026-11-13 営業外収益及び特別利益の計上に関するお知らせ / 2027年3月期 第2四半期(中間期)決算短信〔日本基準〕(非連結)¥41.0¥36.0Oct 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
1-Month High¥41.0Oct 20
1-Month Low¥36.0Nov 20
1-Week Change−5.3%vs Nov 13
1-Month Change−12.2%vs Oct 20

If you had invested ¥100,000 1 month ago, it would be worth ¥87,805 today (−12.2%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −11.9%, while this stock moved −12.2%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥36.0−2−5.26%
Nov 19 (Thu)¥38.0+0+0.00%
Nov 18 (Wed)¥38.0−1−2.56%
Nov 17 (Tue)¥39.0+1+2.63%
Nov 16 (Mon)¥38.0+0+0.00%
Nov 13 (Fri)¥38.0−1−2.56%
Nov 12 (Thu)¥39.0+0+0.00%
Nov 11 (Wed)¥39.0+2+5.41%
Nov 9 (Mon)¥37.0+0+0.00%
Nov 6 (Fri)¥37.0−2−5.13%
2026-09-18 第21回新株予約権発行に関する補足説明資料 / 第三者割当による第21回新株予約権(行使価額修正条項付)の発行及び新株予約権の買…2026-10-05 第三者割当による第21回新株予約権(行使価額修正条項付)の発行価額の払込完了に関…2026-11-13 営業外収益及び特別利益の計上に関するお知らせ / 2027年3月期 第2四半期(中間期)決算短信〔日本基準〕(非連結)¥61.0¥36.0Aug 20Nov 20
Price5-day MA25-day MANikkei 225Disclosures
3-Month High¥61.0Sep 18
3-Month Low¥36.0Nov 20
1-Month Change−12.2%vs Oct 20
3-Month Change−34.5%vs Aug 20

If you had invested ¥100,000 3 months ago, it would be worth ¥65,455 today (−34.5%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −14.8%, while this stock moved −34.5%.

Last 10 Trading Days

DateCloseChange% Change
Nov 20 (Fri)¥36.0−2−5.26%
Nov 19 (Thu)¥38.0+0+0.00%
Nov 18 (Wed)¥38.0−1−2.56%
Nov 17 (Tue)¥39.0+1+2.63%
Nov 16 (Mon)¥38.0+0+0.00%
Nov 13 (Fri)¥38.0−1−2.56%
Nov 12 (Thu)¥39.0+0+0.00%
Nov 11 (Wed)¥39.0+2+5.41%
Nov 9 (Mon)¥37.0+0+0.00%
Nov 6 (Fri)¥37.0−2−5.13%
2026-09-18 第21回新株予約権発行に関する補足説明資料 / 第三者割当による第21回新株予約権(行使価額修正条項付)の発行及び新株予約権の買…2026-10-05 第三者割当による第21回新株予約権(行使価額修正条項付)の発行価額の払込完了に関…2026-11-13 営業外収益及び特別利益の計上に関するお知らせ / 2027年3月期 第2四半期(中間期)決算短信〔日本基準〕(非連結)¥61.0¥36.0May 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
6-Month High¥61.0Sep 18
6-Month Low¥36.0Nov 20
3-Month Change−34.5%vs Aug 20
6-Month Change−29.4%vs May 20

If you had invested ¥100,000 6 months ago, it would be worth ¥70,588 today (−29.4%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −5.6%, while this stock moved −29.4%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥36.0−10.0%
Oct 2026¥40.0−20.0%
Sep 2026¥50.0−5.7%
Aug 2026¥53.0+6.0%
Jul 2026¥50.0+8.7%
Jun 2026¥46.0−11.5%
May 2026¥52.0−5.5%
2026-09-18 第21回新株予約権発行に関する補足説明資料 / 第三者割当による第21回新株予約権(行使価額修正条項付)の発行及び新株予約権の買…2026-10-05 第三者割当による第21回新株予約権(行使価額修正条項付)の発行価額の払込完了に関…2026-11-13 営業外収益及び特別利益の計上に関するお知らせ / 2027年3月期 第2四半期(中間期)決算短信〔日本基準〕(非連結)¥96.0¥36.0Nov 20Nov 20
Price25-day MA75-day MANikkei 225Disclosures
52-Week High¥96.0Mar 25
52-Week Low¥36.0Nov 20
Year to Date−25.0%vs Dec 30
From 52-Week High−62.5%Mar 25

If you had invested ¥100,000 1 year ago, it would be worth ¥61,017 today (−39.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +13.3%, while this stock moved −39.0%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥36.0−10.0%
Oct 2026¥40.0−20.0%
Sep 2026¥50.0−5.7%
Aug 2026¥53.0+6.0%
Jul 2026¥50.0+8.7%
Jun 2026¥46.0−11.5%
May 2026¥52.0−5.5%
Apr 2026¥55.0−20.3%
Mar 2026¥69.0+4.5%
Feb 2026¥66.0+3.1%
Jan 2026¥64.0+33.3%
Dec 2025¥48.0−14.3%
Nov 2025¥56.0―
¥100¥36.0Nov 20, 2023Nov 20, 2026
Price13-week MA26-week MANikkei 225
3-Year High¥100Nov 20, 2023
3-Year Low¥36.0Nov 20, 2026
Annualized Return−28.9%
Max Drawdown−64.0%

If you had invested ¥100,000 3 years ago, it would be worth ¥36,000 today (−64.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +67.8%, while this stock moved −64.0%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥36.0−25.0%
2025¥48.0―
¥197¥36.0Nov 22, 2021Nov 20, 2026
Price13-week MA26-week MANikkei 225
5-Year High¥197Feb 13, 2023
5-Year Low¥36.0Nov 20, 2026
Annualized Return−21.3%
Max Drawdown−81.7%

If you had invested ¥100,000 5 years ago, it would be worth ¥30,252 today (−69.7%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +96.3%, while this stock moved −69.7%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥36.0−25.0%
2025¥48.0―
¥1,450¥36.0Nov 1, 2015Nov 20, 2026
Price1-year MA2-year MANikkei 225
All-Time High¥1,450Apr 2016
All-Time Low¥36.0Nov 2026
Total Change−90.0%vs Nov 2015
Annualized Return−18.8%

If you had invested ¥100,000 in Nov 2015, it would be worth ¥10,028 today (−90.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +196.5%, while this stock moved −90.0%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥36.0−25.0%
2025¥48.0+6.7%
2024¥45.0−48.3%
2023¥87.0−13.0%
2022¥100−10.7%
2021¥112−38.5%
2020¥182−41.9%
2019¥313+49.0%
2018¥210−67.0%
2017¥636−8.4%
2016¥694+162.9%
2015¥264―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Nov 2015). Please check the latest prices before trading.

BrightPath Biotherapeutics Co.,Ltd. (4594) financial indicators

PBR
2.75
ROE
-101.21%
Dividend yield
0.00%

See all financial indicators for BrightPath Biotherapeutics Co.,Ltd. (market cap, DOE, equity ratio, EV, EBITDA, ROIC and more)

PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.

Key features of BrightPath Biotherapeutics Co.,Ltd. (4594)

Business overview

The company is a drug discovery venture focused on developing new cancer immunotherapy drugs, with multiple pipeline candidates ranging from exploratory research to early clinical trials. Its business model is to create or in-license new cancer immunotherapies, handle them from exploratory research through early clinical trials, and license out development, manufacturing and sales rights to pharmaceutical companies in Japan and abroad for license revenue. Drug development generally takes more than 10 years to reach market and requires more funding the later the stage, so a mechanism to recover development investment early is important. Before launch it aims to earn upfront payments at signing and milestone revenue at each development stage, and after launch sales royalty revenue. By advancing multiple pipeline candidates at different stages in parallel, it seeks early recovery of investment and continuous revenue after turning profitable.

Summarized from the annual securities report (fiscal year ended March 2026) filed on EDINET.

Position within Pharmaceuticals (79 companies)

PBR2.75xAbove the sector median of 1.86x (No. 52 from the lowest)
ROE-101.21%No. 50 in the sector (highest first); median 4.17%
Market cap¥5.0 bnNo. 64 in the sector (largest first)

Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.

Price milestones

52-week high¥963/25
52-week low¥3611/20
Current position0.0%Where the low is 0% and the high is 100% (close on 11/20: ¥36)
Year to date-25.0%No. 48 of 77 in the sector (best first)
1 year-39.0%

Based on closing prices (adjusted for stock splits, excluding dividends).

Kabutaro's ranking history

Top 50 gainers1 timesLatest: 9/18 (No. 47)
Top 50 losers2 timesLatest: 10/6 (No. 43)

Gainers and losers have been recorded since 9/2026.

Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.

Recent disclosures (TDnet, in Japanese)

Filings from the past 12 months (6).

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No posts yet. Be the first to write something.

Write on the BrightPath Biotherapeutics Co.,Ltd. board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Japanese stocks in English

Japanese Stock Message Board: stocks available in English

Other boards in English